Conditional survival does not improve over time in metastatic castration‐resistant prostate cancer patients undergoing docetaxel
The Prostate · 2023
DOI: 10.1002/pros.24583 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Prostate, 2023. Verfasst von Daniele Modonutti und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Vattikuti Urology Institute, Henry…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit nennt 27 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
To investigate the conditional overall survival (OS) of metastatic castration‐resistant prostate cancer (mCRPC) patients receiving docetaxel chemotherapy.
Methods
We used deidentified patient‐level data from the Prostate Cancer DREAM Challenge database and the control arm of the ENTHUSE 14 trial. We identified 2158 chemonaïve mCRPC patients undergoing docetaxel chemotherapy in the five randomized clinical trials. The 6‐month conditional OS was calculated at times 0, 6, 12, 18, and 24 months from randomization. Survival curves of each group were compared using the log‐rank test. Patients were then stratified into low‐ and high‐risk groups based on the median predicted value of our recently published nomogram predicting OS in mCRPC patients.
Results
Nearly half (45%) of the study population was aged between 65 and 74 years. Median interquartile range prostate‐specific antigen for the overall cohort was 83.2 (29.6–243) ng/mL, and 59% of patients had bone metastasis with or without lymph node involvement. The 6‐month conditional survival rates at 0, 6, 12, 18, and 24 months for the entire cohort were 93% (95% confidence interval [CI]: 92–94), 82% (95% CI: 81–84), 76% (95% CI: 73–78), 75% (95% CI: 71–78), and 71% (95% CI: 65–76). These rates were, respectively, 96% (95% CI: 95–97), 92% (95% CI: 90–93), 84% (95% CI: 81–87), 81% (95% CI: 77–85), and 79% (95% CI: 72–84) in the low‐risk group and 89% (95% CI: 87–91), 73% (95% CI: 70–76), 65% (95% CI: 60–69), 64% (95% CI: 58–70), and 58% (95% CI: 47–67) in the high‐risk group.
Conclusion
The conditional OS for patients undergoing docetaxel chemotherapy tends to plateau over time, with the main drop in conditional OS happening during the first year from initiating docetaxel treatment. That is the longer a patient survives, the more likely they are to survive further. This prognostic information could be a useful tool for a more accurate tailoring of both follow‐up and therapies. Patient Summary In this report, we looked at the future survival in months of patients with metastatic castration resistant prostate cancer on chemotherapy who have already survived a certain period. We found that the longer time that a patient survives, the more likely they will continue to survive. We conclude that this information will help physicians tailor follow‐ups and treatments for patients for a more accurate personalized medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Vattikuti Urology Institute, Henry Ford Health System, Detroit, Michigan, USA.
- Department of Surgery, Oncology and Gastroenterology-Urology, University Hospital of Padova, Padova, Italy.
- Department of Urology, Vattikuti Urology Institute, Henry Ford Hospital, Detroit, Michigan, USA.
- Department of Medicine, School of Medicine, Wayne State University, Detroit, Michigan, USA.
- Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Division of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Firas Abdollah
Zitieren
APA
Modonutti, D., Majdalany, S. E., Butaney, M., Davis, M. J., Corsi, N., Sood, A., Trinh, Q. D., Cole, A. P., Rogers, C. G., Novara, G., & Abdollah, F. (2023). Conditional survival does not improve over time in metastatic castration‐resistant prostate cancer patients undergoing docetaxel. The Prostate. https://doi.org/10.1002/pros.24583
Vancouver
Modonutti D, Majdalany SE, Butaney M, Davis MJ, Corsi N, Sood A, et al. Conditional survival does not improve over time in metastatic castration‐resistant prostate cancer patients undergoing docetaxel. The Prostate. 2023. doi:10.1002/pros.24583
BibTeX
@article{Modonutti2023,
author = {Modonutti, Daniele and Majdalany, Sami E and Butaney, Mohit and Davis, Matthew J and Corsi, Nicholas and Sood, Akshay and Trinh, Quoc-Dien and Cole, Alexander P and Rogers, Craig G and Novara, Giacomo and Abdollah, Firas},
title = {Conditional survival does not improve over time in metastatic castration‐resistant prostate cancer patients undergoing docetaxel},
journal = {The Prostate},
year = {2023},
doi = {10.1002/pros.24583}
}
EUVIMED